Latest news

• With Spiriva under pressure, Boehringer moves to bolster pipeline

  Privately-held Boehringer has been trying to patients from Spiriva to new combination Spiolto (tiotropium/olodaterol), with some payer resistance, but in the meantime Jardiance and Ofev have taken up the

• Boehringer Ingelheim calls for "strong and united" Europe

  Boehringer is hoping to migrate patients to new combination therapy Spiolto/Stiolto (tiotropium plus olodaterol) but with the asthma and COPD category becoming increasingly crowded and price-sensitive the combination is

• Boehringer starts to feel impact of Spiriva generics

  combination therapy Spiolto/Stiolto (tiotropium plus olodaterol).

• GSK's triple COPD therapy tops Symbicort in phase III trial

  Ingelheim's Spiolto (tiotropium/olodaterol).

• GSK brings forward triple COPD therapy filing in US

  GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto